GlassScriptPhysician profile
Yashvant D Patel
NPI 1760483481
$967.04
in general payments reported to CMS, 2019-2025
15 companies · $13.83 in 2025
The $13.83 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $247 · 2021: $80.32 · 2022: $195 · 2023: $85.06 · 2024: $16.01 · 2025: $13.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $114.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $304.14 | 2019-2025 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $149.07 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $123.69 | 2022-2023 | Verquvo |
| Sanofi-Aventis U.S. LLC | $86.68 | 2019 | |
| Novartis Pharmaceuticals Corporation | $77.04 | 2019-2022 | |
| Lilly USA, LLC | $50.73 | 2021-2022 | |
| Amarin Pharma, INC. | $32.19 | 2019 | |
| Novo Nordisk INC | $29.32 | 2019-2020 | |
| Abbvie INC. | $22.95 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.58 | 2022 | |
| Amgen INC. | $17.27 | 2023 | Repatha |
| Idorsia Pharmaceuticals US INC | $15.83 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $14.02 | 2020 | |
| Eisai INC. | $12.62 | 2021 | |
| Pfizer INC. | $11.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yashvant Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.